Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus ...

Of entecavir-treated patients, 19% achieved undetectable HBV DNA levels versus 1% in the LVD-treated group (p < 0.0001) and 61% in the entecavir group achieved normalization of ALT versus 15% in ...

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Entecavir Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.A thorough market analysis on ...

Entecavir (Baraclude), an inhibitor of hepatitis B virus DNA polymerase, is the latest approved antiviral agent for chronic hepatitis B. Researchers examined the efficacy of entecavir in two ...

Entecavir, currently in Phase III clinical development, is an investigational oral nucleoside analogue discovered at Bristol-Myers Squibb which is a selective inhibitor of the hepatitis B virus.

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology, 2010; DOI: 10.1002/hep.23785 ...

Participants treated with entecavir were older, had a lower body mass index, and lower platelet count vs those treated with tenofovir. Of the cohort, 1901 patients (74.8%) received entecavir, and ...

A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the European ENTEBE study presented at ...

Entecavir/tenofovir combination therapy was generally safe and well-tolerated. Only 3% of participants in the study experienced serious adverse events, none of which were considered treatment-related, ...

The aim of this study was to compare the efficacy of lamivudine vs entecavir in the prevention of hepatitis B virus (HBV) reactivation in HBV surface Ag (HBsAg)-positive patients undergoing ...

The Committee discussed the clinical effectiveness of entecavir in treating chronic hepatitis B and considered all of the available evidence. It acknowledged that in RCTs entecavir had been ...

The manufacturer approached the initial decision problem by comparing entecavir monotherapy with interferon alfa-2a and -2b, peginterferon alfa-2a, lamivudine, adefovir dipivoxil and telbivudine. The ...